🇧🇪 Belgium Country × Condition
myelofibrosis Clinical Trials in Belgium
Active clinical trials for myelofibrosis with research sites in Belgium. All data sourced live from ClinicalTrials.gov — updated daily.
Active Trials: 2 // Recruiting: 2 Phases: Phase 1, Phase 2, Phase 2 // Updated: Daily
Total Trials
2
Recruiting Now
2
Country
🇧🇪 Belgium
Active Trials in Belgium (2)
NCT04176198 Phase 1, Phase 2
Recruiting
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
Enrollment
240 pts
Country
🇧🇪 Belgium
Sumitomo Pharma America, Inc.
View Trial → NCT05980806 Phase 2
Recruiting
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
Enrollment
58 pts
Country
🇧🇪 Belgium
Karyopharm Therapeutics Inc
View Trial → Frequently Asked Questions
How many myelofibrosis clinical trials are active in Belgium?
There are currently 2 active clinical trials for myelofibrosis with sites in Belgium, of which 2 are actively recruiting patients.
How can I join a myelofibrosis clinical trial in Belgium?
To join a myelofibrosis clinical trial in Belgium, select a recruiting trial below and check the eligibility criteria. Contact the trial's principal investigator or the listed site in Belgium directly. All trials listed here are sourced from ClinicalTrials.gov, the official U.S. registry of clinical studies.
What phases are myelofibrosis trials in Belgium?
Active myelofibrosis trials in Belgium span Phase 1, Phase 2, Phase 2. Phase I trials test safety, Phase II test efficacy, and Phase III compare against standard treatments in larger patient populations.
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology